|
PredicTOR: predicting patient response to mTOR pathway inhibitors prior to treatm
|
2R44CA123994-04
|
$750,000
|
$255,000
|
Lebowitz, Michael
|
20/20 GENESYSTEMS, INC.
|
|
Phase O Carboplatin Microdosing Diagnostics Trial
|
N43CO100133-000
|
$195,550
|
$195,550
|
Henderson, Paul
|
ACCELERATED MEDICAL DIAGNOSTICS, LLC
|
|
PROSTATE, LUNG, COLO-RECTAL AND OVARIAN (PLCO) CANCER SCREENING TRIAL EXPANSION F
|
N01CN075022-066
|
$1,291,459
|
$322,865
|
Fouad, Mona
|
ALABAMA UNIV BIRMINGHAM:1109410
|
|
The Role of ATF3 in the DNA Damage Response
|
1R01CA139107-01A2
|
$262,280
|
$86,552
|
Yan, Chunhong
|
ALBANY MEDICAL COLLEGE
|
|
Core Support for Cancer Center
|
3P30CA013330-38S2
|
$100,000
|
$10,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Core Support for Cancer Center
|
5P30CA013330-38
|
$3,927,232
|
$392,723
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Serum Levels of EGFR-Signaling-Network Activators/Inhibitor and Lung Cancer Risk
|
1R01CA143597-01A1
|
$702,820
|
$702,820
|
HO, GLORIA
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Taxol: Mechanisms of Action and Resistance
|
2R01CA077263-10A2
|
$415,000
|
$415,000
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
A mouse model of stem cell deregulation and lung cancer
|
5R01CA076354-10
|
$264,921
|
$264,921
|
LOCKER, JOSEPH
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Determinants of Resistance to Erlotinib in NSCLC
|
5R01CA113630-05
|
$286,106
|
$286,106
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Transition State Analogues as Modulators of DNA Methylation
|
5R01CA135405-03
|
$270,000
|
$270,000
|
SCHRAMM, VERN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
2U10CA014958-36
|
$127,404
|
$3,822
|
SPARANO, JOSEPH
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Risk for Lung Cancer, Asthma, and COPD; Integrating Clinical and Airway Biomarker
|
1K24CA139054-01A1
|
$167,705
|
$167,705
|
SPIVACK, SIMON
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
Field of Injury Based Biomarkers for Lung Cancer
|
4R44CA139803-02
|
$1,823,081
|
$1,823,081
|
Hallam, Stephanie
|
ALLEGRO DIAGNOSTICS, INC.
|
|
Adolescent Smoking Cessation in Pediatric Primary Care
|
1R01CA140576-01A2
|
$578,712
|
$549,776
|
KLEIN, JONATHAN
|
AMERICAN ACADEMY OF PEDIATRICS
|
|
Community Clinical Oncology Program
|
2U10CA037422-23
|
$4,179,081
|
$543,281
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group
|
3U10CA021661-34S2
|
$1,198,505
|
$119,851
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Community Clinical Oncology Program Research Base
|
3U10CA037422-22S2
|
$28,500
|
$3,705
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Community Clinical Oncology Program Research Base
|
3U10CA037422-22S3
|
$1,208,966
|
$157,166
|
CURRAN, WALTER
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
RTOG Tissue Bank
|
3U24CA114734-05S1
|
$1,040,063
|
$104,006
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-34
|
$12,451,705
|
$1,245,171
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
American College of Radiology Imaging Network
|
5U01CA080098-12
|
$9,041,302
|
$1,130,163
|
Schnall, Mitchell
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
Targeted tumoricidal bacteria
|
2R44CA126023-02
|
$374,950
|
$93,738
|
ZHAO, MING
|
ANTICANCER, INC.
|
|
MULTIFUNCTIONAL DRUG-DELIVERY STENT WITH NANOPOROUS COAT
|
N43CO100046-000
|
$199,999
|
$199,999
|
Shenoy, Narmada
|
ARAVASC, INC
|
|
Molecular Target Focused Discovery of Anticancer Drugs
|
5R01CA090441-08
|
$381,250
|
$53,375
|
PETTIT, GEORGE
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Effect of True Puff Profile Replication on Machine-Generated Smoke Constituents
|
5R21CA133893-02
|
$146,892
|
$139,547
|
Gordon, Sydney
|
BATTELLE CENTERS/PUB HLTH RES & EVALUATN
|
|
Roll Your Own (RYO) Cigarettes: Prevalence, Smoking Behavior and Toxin Exposure
|
5R01CA138973-02
|
$514,087
|
$514,087
|
Pickworth, Wallace
|
BATTELLE CENTERS/PUB HLTH RES & EVALUATN
|
|
Bay Area Tumor Institute CCOP
|
5U10CA045461-21
|
$461,201
|
$41,508
|
Feusner, James
|
BAY AREA TUMOR INSTITUTE
|
|
Reducing Missed And Delayed Diagnoses In Cancer: Lessons From Aviation
|
5K23CA125585-04
|
$141,750
|
$46,778
|
SINGH, HARDEEP
|
BAYLOR COLLEGE OF MEDICINE
|
|
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment
|
1R01CA140674-01A1
|
$300,870
|
$99,287
|
PINNEY, KEVIN
|
BAYLOR UNIVERSITY
|
|
Virginia Mason Community Clinical Oncology Program
|
3U10CA035192-26S1
|
$487,529
|
$43,878
|
Vuky, Jacqueline
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
Eastern Cooperative Oncology Group
|
2U10CA080775-12
|
$104,956
|
$3,149
|
ATKINS, MICHAEL
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Role of Nicotine in Lung Carcinogenesis
|
5R01CA124490-04
|
$323,000
|
$323,000
|
CHEN, CHANGYAN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Role of EGFR mutations and new therapeutics in lung cancer
|
5R00CA126026-04
|
$249,000
|
$249,000
|
Kobayashi, Susumu
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Role of DOK family proteins in lung tumor suppression
|
1R01CA142787-01
|
$360,618
|
$360,618
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Role of POZ-zinc finger proteins in tumorigenesis.
|
2R01CA102142-06A1
|
$340,356
|
$115,721
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
The function of RhoBTB proteins
|
5R01CA113559-05
|
$293,000
|
$73,250
|
Soltoff, Stephen
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Circulating Tumor Cells in Non-Small Cell Lung Cancer
|
5R01CA125653-04
|
$337,278
|
$337,278
|
Nieva, Jorge
|
BILLINGS CLINIC FOUNDATION
|
|
Rapid, Label-free, Multiplex Detection of MicroRNAs
|
1R43CA153467-01
|
$99,521
|
$99,521
|
ROSENDAHL, MARY
|
BIOPTIX DIAGNOSTICS, INC.
|
|
The MB-CCOP at Boston Medical Center
|
1U10CA139519-01A1
|
$706,684
|
$113,069
|
KACHNIC, LISA
|
BOSTON MEDICAL CENTER
|
|
Cancer Disparities in California
|
1R03CA153063-01
|
$81,250
|
$26,813
|
Boehmer, Ulrike
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Health Advocates as a Vehicle to Improve Treatment for Smokers in Public Housing
|
5R01CA141587-02
|
$654,139
|
$621,432
|
BROOKS, DANIEL
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
A Follow-up Study for Causes of Illness in Black Women
|
5R01CA058420-17
|
$1,766,131
|
$264,920
|
Rosenberg, Lynn
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Airway gene expression in smokers: an early diagnostic biomarker for lung cancer
|
5R01CA124640-04
|
$308,750
|
$308,750
|
SPIRA, Avrum
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Improving decisions about evaluating pulmonary nodules for lung cancer
|
5K07CA138772-03
|
$169,236
|
$169,236
|
Wiener, Renda
|
BOSTON UNIVERSITY MEDICAL CAMPUS
|
|
Cancer and Leukemia Group B CCOP Research Base
|
2U10CA037447-26
|
$2,316,114
|
$254,773
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
3U10CA031946-29S3
|
$8,129,333
|
$487,760
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B
|
7U10CA031946-29
|
$11,034,745
|
$662,085
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Cancer and Leukemia Group B Human Specimen Repositories
|
7U24CA114725-06
|
$1,155,595
|
$577,798
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Validation of Prognostic and Diagnostic molecular tests in Mesothelioma
|
5R01CA120528-05
|
$301,617
|
$301,617
|
BUENO, RAPHAEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
Total relevant funding to Lung for this search: $281,931,477
|